Is PT-141 (Bremelanotide) Legal in Georgia?

What Exactly Is PT-141 (Bremelanotide)?

PT-141, sold under the brand name Vyleesi, is a synthetic cyclic heptapeptide melanocortin receptor agonist. The FDA approved it on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women. [1] Unlike phosphodiesterase-5 inhibitors, bremelanotide acts centrally on melanocortin receptors in the brain rather than on vascular smooth muscle, which is why it carries a meaningful side-effect profile including nausea and transient blood-pressure changes.

Mechanism of Action

Bremelanotide binds to MC1R and MC4R receptors. MC4R activation in the hypothalamus is the pathway most associated with sexual motivation. The drug's half-life is approximately 2.7 hours. [2] Because it works on central pathways, it has been studied in both women and men, though only the female HSDD indication carries FDA approval.

Why the Brand vs. Compounded Distinction Matters

The brand product Vyleesi is manufactured by AMAG Pharmaceuticals (now Palatin Technologies' licensee) as a single-dose auto-injector. Compounded bremelanotide is prepared by licensed 503A compounding pharmacies using bulk active pharmaceutical ingredient (API). These are legally distinct products with different regulatory pathways, and the distinction directly shapes what a Georgia patient can obtain and from whom.

Federal Legal Framework Governing PT-141

Understanding Georgia law requires understanding federal law first, because federal rules set the floor that every state must at minimum meet.

FDA-Approved Drug Status

The FDA approved Vyleesi under NDA 210557. [1] Approval means bremelanotide is a Schedule V-equivalent in terms of prescriptibility: any practitioner licensed to prescribe in their state may write a prescription for an FDA-approved drug. No federal statute prohibits a licensed Georgia physician, physician assistant, or nurse practitioner from prescribing Vyleesi.

DEA Scheduling

Bremelanotide does not appear on the DEA controlled-substance schedules. [3] This matters practically: prescribers do not need a DEA-number-specific controlled-substance designation to prescribe it, and pharmacies do not face the additional recordkeeping burden associated with Schedule II-V drugs.

The FDA Bulk Compounding Lists and 503A Rules

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits licensed compounding pharmacies to prepare individualized prescriptions using bulk drug substances. However, the FDA maintains a "Bulks List" identifying substances that may or may not be used in 503A compounding. [4]

As of mid-2025, bremelanotide does not appear on the FDA's affirmative 503A bulk-substances list, nor does it appear on the list of substances prohibited from compounding. This places it in a regulatory gray zone at the federal level for 503A compounding. Pharmacies that compound bremelanotide operate under the position that the existence of an FDA-approved product does not automatically prohibit 503A compounding when a prescriber determines a clinical need exists, but the FDA has increased scrutiny of such compounding. [4]

Section 503B outsourcing facilities face a stricter standard: they may only compound drugs from the FDA's affirmative 503B bulks list, and bremelanotide does not currently appear there. [5] Patients receiving compounded PT-141 dispensed from a 503B facility would be receiving a product outside that facility's authorized scope.

The practical consequence: compounded PT-141 from a 503A pharmacy prepared for a specific patient under a valid individual prescription exists in a legally defensible but not fully settled federal space. Patients should ask their telehealth provider specifically which type of pharmacy will dispense their medication.

Georgia-Specific Legal Framework

Georgia does not have a separate state law that adds restrictions on top of FDA-approved drugs. A licensed prescriber in Georgia may legally prescribe Vyleesi (branded bremelanotide) to any patient for whom it is clinically appropriate, including off-label indications, under the Georgia Medical Practice Act (O.C.G.A. Title 43, Chapter 34). [6]

Georgia State Board of Pharmacy Rules

The Georgia State Board of Pharmacy regulates compounding under O.C.G.A. Title 26, Chapter 4. Georgia has adopted USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile) compounding standards as binding requirements. [7] Because PT-141 is a sterile injectable, any Georgia-licensed compounding pharmacy preparing it must comply with USP 797 standards for sterile preparation.

Georgia pharmacies that compound patient-specific prescriptions operate as 503A facilities under both state and federal law. As long as the prescription is patient-specific, issued by a licensed Georgia prescriber, and dispensed by a Georgia-licensed (or out-of-state licensed) 503A pharmacy registered to ship into Georgia, the transaction is legal under state law. Georgia also permits patients to receive compounded prescriptions from out-of-state 503A pharmacies that hold non-resident pharmacy permits issued by the Georgia Board of Pharmacy. [7]

Off-Label Prescribing in Men

Georgia's Medical Practice Act permits off-label prescribing consistent with the standard of care. [6] Men seeking PT-141 for sexual dysfunction may receive it legally if a licensed Georgia prescriber determines it is clinically appropriate. A 2012 study published in the Journal of Sexual Medicine (N=271) found that bremelanotide produced statistically significant improvements in erectile function scores in men with erectile dysfunction, though the drug was never submitted for FDA approval in this population. [8] Prescribers should document their clinical rationale when prescribing off-label.

How to Get PT-141 Legally in Georgia

There are three legitimate access pathways for Georgia residents.

Pathway 1: In-Person Visit to a Licensed Georgia Prescriber

Any Georgia-licensed physician (M.D. Or D.O.), physician assistant, or advanced practice registered nurse (APRN) with prescriptive authority may evaluate a patient and write a prescription for Vyleesi or compounded bremelanotide. The prescription can then be filled at any retail pharmacy that stocks Vyleesi or at a licensed compounding pharmacy.

Pathway 2: Telehealth Prescription

Georgia law permits synchronous audio-video telehealth encounters to establish a valid prescriber-patient relationship. Under O.C.G.A. Section 33-24-56.4 and the Georgia Composite Medical Board's telehealth rules, a prescriber may issue a prescription following a telehealth visit if the standard of care is met. [9] Telehealth platforms specializing in sexual health and hormone therapy routinely evaluate patients for HSDD and issue bremelanotide prescriptions to Georgia addresses.

The prescriber must conduct a clinical evaluation. A prescription issued without a legitimate medical evaluation, regardless of platform, does not comply with Georgia or federal law.

Pathway 3: Specialty Clinics and Medical Spas

Georgia has numerous functional medicine clinics, men's health clinics, and hormone optimization practices that prescribe peptide therapies including bremelanotide. These practices prescribe under the same legal framework as any other prescriber. Patients should verify the prescribing clinician holds an active Georgia license, which can be confirmed through the Georgia Secretary of State Professional License lookup tool.

Clinical Evidence Supporting PT-141 Use

The FDA approval of bremelanotide rested on two Phase 3 randomized controlled trials: RECONNECT Study 1 and RECONNECT Study 2.

In RECONNECT Study 1 (N=394 premenopausal women with HSDD), bremelanotide 1.75 mg demonstrated a statistically significant increase from baseline in the number of satisfying sexual events (SSEs) compared to placebo at 24 weeks (mean change of 0.7 SSEs per month vs. 0.4 for placebo, P<0.001). [1] Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) scores showed a mean decrease of 11.0 points with bremelanotide versus 8.0 points for placebo (P<0.001). [1]

The FDA label notes that the clinical meaningfulness of these differences was modest, and the agency required a Risk Evaluation and Mitigation Strategy (REMS) program at approval, though the REMS was subsequently removed after post-marketing safety data were reviewed. [1]

A 2019 commentary in the New England Journal of Medicine noted that patient-reported outcomes in sexual medicine trials carry inherent measurement challenges, and that the RECONNECT results, while statistically significant, reflected modest absolute effect sizes. [10] Prescribers should discuss realistic expectations with patients before initiating therapy.

Regarding safety, the most common adverse effects in the RECONNECT trials were nausea (40% bremelanotide vs. 14% placebo), flushing (20% vs. 3%), and headache (11% vs. 3%). [1] Transient increases in blood pressure averaging 2-3 mmHg systolic and 1-2 mmHg diastolic were observed. The drug is contraindicated in patients with known cardiovascular disease. [1]

What Georgia Residents Should Know Before Starting PT-141

Questions to Ask Your Prescriber

Before accepting a prescription, a Georgia patient should confirm: (1) whether the pharmacy is a licensed 503A compounder or a 503B outsourcing facility; (2) whether the pharmacy holds a valid Georgia non-resident pharmacy permit if it is shipping from out of state; and (3) whether the prescriber has documented the clinical basis for the prescription in the medical record.

Insurance and Cost Considerations

Vyleesi is rarely covered by commercial insurance in Georgia. The cash price per auto-injector is approximately $900-$1,100. Palatin Technologies has historically offered a patient savings program that reduces out-of-pocket costs for commercially insured patients. Compounded bremelanotide from a 503A pharmacy typically costs $80-$200 per vial depending on concentration and volume, though pricing varies by pharmacy.

Drug Interactions and Contraindications

Bremelanotide significantly slows gastric emptying and may reduce oral drug absorption when taken around the same time as other medications. [1] The FDA label specifically warns against concomitant use with naltrexone. Patients on opioid pain medications should discuss this interaction with their prescriber, as bremelanotide may reduce opioid efficacy.

Regulatory Red Flags: What Is Not Legal in Georgia

Purchasing PT-141 without a prescription from domestic or international online sources is not legal under federal law regardless of state. The FD&C Act prohibits dispensing prescription drugs without a valid prescription. [11] Research-chemical vendors sometimes market bremelanotide as "not for human use" to evade FDA oversight; purchasing from these sources violates federal law and carries meaningful safety risks from unverified purity and concentration.

Compounding pharmacies that ship PT-141 without requiring a patient-specific prescription from a licensed prescriber are operating outside 503A rules. The FDA has issued warning letters to compounders selling peptides without valid prescriptions. [12] Georgia residents should verify that any online pharmacy requires a prescription and holds the appropriate licenses before purchasing.